The optimal combination of Lysinopril and Amlodipine for the treatment of patients with hypertension

G. Junusbekova, M. Tundybayeva, T. Leonovich, Manshuk Yeshniyazova, Rizvangul Namatova, S. Alimbayeva, Gani Tulepbergenov, Aizhan Kubeyeva
{"title":"The optimal combination of Lysinopril and Amlodipine for the treatment of patients with hypertension","authors":"G. Junusbekova, M. Tundybayeva, T. Leonovich, Manshuk Yeshniyazova, Rizvangul Namatova, S. Alimbayeva, Gani Tulepbergenov, Aizhan Kubeyeva","doi":"10.31082/1728-452x-2020-211-212-1-2-31-39","DOIUrl":null,"url":null,"abstract":"Arterial hypertension (AH) remains one of the most common diseases in the world. Reducing cardiovascular risk of mortality from cardiovascular complications is a priority in the treatment of hypertension. Targets of hypertension therapy is to achieve SBP/DBP <140/80 mm Hg. article, regardless of cardiovascular risk and comorbidity. The choice of antihypertensive therapy depends on blood pressure levels, the presence or absence of concomitant diseases, lesion of target organs. Effective and long-lasting control of AH proved by the use of combinations of antihypertensive drugs, including antagonists and ACE inhibitors. The purpose of the study. Evaluation of clinical efficacy and safety of fixed combination antihypertensive therapy using lisinopril combined with amlodipine in patients with hypertension. Material and methods. The study included 30 respondents from essential hypertension II-III degree (ESH/ESC, 2018) aged 35 to 75 years. Patients were treated with the schema a (lisinopril 10 mg, amlodipine 5 mg) and scheme b (lisinopril 20 mg, amlodipine 10 mg) fixed combination therapy with the drug VivaCor® once in the morning. The period of observation was 3 months. At the time of inclusion and at the end of the study all respondents was performed echocardiography, daily monitoring of blood pressure, evaluation of laboratory and instrumental methods of research. Results and discussion. The combination of lisinopril with amlodipine has a fairly high antihypertensive activity, provides a significant cardioprotective effect and is an integral part of antihypertensive therapy in the long-term strategy of administering patients with high hypertensive / very high total cardiovascular risk. Conclusions: 1. The use of a fixed combination of lisinopril and amlodipine in patients with hypertension instead of free or other two-component combinations leads to its target level within 3 months of therapy. 2. Taking a fixed combination of lisinopril and amlodipine is effective and safe. 3. Therapy using the combined drug VivaCor® in patients with high / very high risk of hypertension prevents further pathological remodeling of the heart. 4. The combination of amlodipine and lisinopril is metabolically neutral and well tolerated by patients. Keywords: arterial hypertension, lisinopril, amlodipine, VivaCor.","PeriodicalId":14842,"journal":{"name":"Journal \"Medicine\"","volume":"50 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal \"Medicine\"","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31082/1728-452x-2020-211-212-1-2-31-39","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Arterial hypertension (AH) remains one of the most common diseases in the world. Reducing cardiovascular risk of mortality from cardiovascular complications is a priority in the treatment of hypertension. Targets of hypertension therapy is to achieve SBP/DBP <140/80 mm Hg. article, regardless of cardiovascular risk and comorbidity. The choice of antihypertensive therapy depends on blood pressure levels, the presence or absence of concomitant diseases, lesion of target organs. Effective and long-lasting control of AH proved by the use of combinations of antihypertensive drugs, including antagonists and ACE inhibitors. The purpose of the study. Evaluation of clinical efficacy and safety of fixed combination antihypertensive therapy using lisinopril combined with amlodipine in patients with hypertension. Material and methods. The study included 30 respondents from essential hypertension II-III degree (ESH/ESC, 2018) aged 35 to 75 years. Patients were treated with the schema a (lisinopril 10 mg, amlodipine 5 mg) and scheme b (lisinopril 20 mg, amlodipine 10 mg) fixed combination therapy with the drug VivaCor® once in the morning. The period of observation was 3 months. At the time of inclusion and at the end of the study all respondents was performed echocardiography, daily monitoring of blood pressure, evaluation of laboratory and instrumental methods of research. Results and discussion. The combination of lisinopril with amlodipine has a fairly high antihypertensive activity, provides a significant cardioprotective effect and is an integral part of antihypertensive therapy in the long-term strategy of administering patients with high hypertensive / very high total cardiovascular risk. Conclusions: 1. The use of a fixed combination of lisinopril and amlodipine in patients with hypertension instead of free or other two-component combinations leads to its target level within 3 months of therapy. 2. Taking a fixed combination of lisinopril and amlodipine is effective and safe. 3. Therapy using the combined drug VivaCor® in patients with high / very high risk of hypertension prevents further pathological remodeling of the heart. 4. The combination of amlodipine and lisinopril is metabolically neutral and well tolerated by patients. Keywords: arterial hypertension, lisinopril, amlodipine, VivaCor.
赖辛普利与氨氯地平联合应用治疗高血压的最佳方案
动脉高血压(AH)仍然是世界上最常见的疾病之一。降低心血管并发症导致的心血管死亡风险是高血压治疗的重点。高血压治疗的目标是收缩压/舒张压<140/80 mm Hg. article,不考虑心血管风险和合并症。降压治疗的选择取决于血压水平、有无伴发疾病、靶器官病变。联合使用抗高血压药物(包括拮抗剂和ACE抑制剂)可有效和持久地控制AH。研究的目的。评价赖诺普利联合氨氯地平固定联合降压治疗高血压患者的临床疗效和安全性。材料和方法。该研究包括30名年龄在35至75岁之间的原发性高血压II-III度(ESH/ESC, 2018)的受访者。患者采用方案a(赖诺普利10 mg,氨氯地平5 mg)和方案b(赖诺普利20 mg,氨氯地平10 mg)与药物VivaCor®固定联合治疗,每日早晨1次。观察期为3个月。在纳入研究时和研究结束时,所有受访者都进行了超声心动图检查,每天监测血压,评估实验室和仪器研究方法。结果和讨论。赖诺普利与氨氯地平联用具有较高的降压活性,具有显著的心脏保护作用,是高血压/心血管总风险极高患者长期降压治疗的重要组成部分。结论:1。在高血压患者中使用赖诺普利和氨氯地平的固定组合,而不是自由或其他双组分组合,可在治疗3个月内达到目标水平。2. 赖诺普利与氨氯地平固定联合用药是安全有效的。3.使用联合药物VivaCor®治疗高/极高风险高血压患者可防止心脏进一步的病理性重塑。4. 氨氯地平和赖诺普利联合使用代谢中性,患者耐受性良好。关键词:高血压,赖诺普利,氨氯地平,VivaCor。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信